Cambiar Investors LLC reduced its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 27.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 410,900 shares of the medical research company’s stock after selling 154,627 shares during the period. Cambiar Investors LLC owned about 0.26% of Bruker Corporation worth $12,224,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Koch Industries Inc. increased its stake in Bruker Corporation by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock worth $324,000 after buying an additional 322,252 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Bruker Corporation by 4.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 524,525 shares of the medical research company’s stock worth $12,238,000 after buying an additional 24,115 shares during the period. AJO LP purchased a new stake in Bruker Corporation during the 2nd quarter worth approximately $46,075,000. Cubist Systematic Strategies LLC increased its stake in Bruker Corporation by 186.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock worth $475,000 after buying an additional 10,723 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Bruker Corporation by 6.8% during the 2nd quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after buying an additional 123,322 shares during the period. 65.47% of the stock is currently owned by hedge funds and other institutional investors.
Bruker Corporation (NASDAQ BRKR) traded up $0.56 during midday trading on Tuesday, reaching $32.39. 657,700 shares of the company’s stock traded hands, compared to its average volume of 632,791. Bruker Corporation has a 12 month low of $21.03 and a 12 month high of $35.16. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. The firm has a market cap of $5,130.00, a PE ratio of 27.20, a PEG ratio of 2.69 and a beta of 1.05.
Bruker Corporation (NASDAQ:BRKR) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter in the prior year, the business posted $0.32 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. sell-side analysts predict that Bruker Corporation will post 1.19 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Stockholders of record on Monday, December 4th will be issued a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.49%. Bruker Corporation’s payout ratio is 17.02%.
Several equities research analysts recently weighed in on the stock. Citigroup Inc. upped their target price on shares of Bruker Corporation from $29.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Cowen and Company reaffirmed a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a research note on Friday, November 3rd. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Wednesday, November 8th. Bank of America Corporation raised shares of Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a research note on Friday, November 3rd. Finally, J P Morgan Chase & Co raised shares of Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 target price on the stock in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $29.64.
In other news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the transaction, the vice president now owns 60,524 shares in the company, valued at approximately $1,813,904.28. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 35.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Cambiar Investors LLC Sells 154,627 Shares of Bruker Corporation (BRKR)” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/14/cambiar-investors-llc-sells-154627-shares-of-bruker-corporation-brkr.html.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR).
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.